Royalty Report: Medical, cell therapy, Diagnostic – Collection: 366319

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Medical
  • cell therapy
  • Diagnostic
  • Disease
  • Drugs
  • Stem cells

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 366319

License Grant
Licensor will grant to the undisclosed joint venture company an exclusive, sublicensable, royalty-bearing right and license to the relevant party’s background intellectual property as required solely to manufacture, distribute and market and sell such party’s products within the territory of Australia.
License Property
Product is in the field of Cell and Gene therapies development and development of the Company’s worldwide POCare network.

Our Point of Care (“POCare”) Platform is comprised of three enabling components a multitude of licensed cell based POCare Therapeutics that are produced in closed, automated POCare technology systems and a collaborative POCare Network. Our therapies include, but are not limited to, autologous, cell-based immunotherapies, therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration.

The POCare platform is designed to collect, process and supply cells within the patient care setting for various therapeutic treatments. The goal of the platform is to reduce the cost and complexity of supplying cell and gene therapies, as well as elevate quality standards by integrating automated processing units and proprietary technologies.

Field of Use
Field of use is a platform defined as a process of collecting, processing, and administering cells within the patient care environment, namely through academic partnerships in a hospital setting.

IPSCIO Record ID: 366320

License Grant
Australian Licensor will grant to the undisclosed joint venture company an exclusive, sublicensable, royalty-bearing right and license to the relevant party’s background intellectual property as required solely to manufacture, distribute and market and sell such party’s products within the territory of Australia.
License Property
Product is in the field of Cell and Gene therapies development and development of the Company’s worldwide POCare network.

Our Point of Care (“POCare”) Platform is comprised of three enabling components a multitude of licensed cell based POCare Therapeutics that are produced in closed, automated POCare technology systems and a collaborative POCare Network. Our therapies include, but are not limited to, autologous, cell-based immunotherapies, therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration.

Field of Use
Field of use is a platform defined as a process of collecting, processing, and administering cells within the patient care environment, namely through academic partnerships in a hospital setting.

IPSCIO Record ID: 374859

License Grant
The Parties collaborate in the evaluation, continued development, validation, and use of Licensor’s platform designed for the early detection and diagnosis of diseases and conditions and for quality control and monitoring purposes, in conjunction with the Licensee’s systems and Licensor grants to the Licensee a worldwide exclusive license to sell such products in the Licensee’s point-of-care network of hospitals, clinics and institutions for quality control and monitoring of manufacturing and processing of autologous immune cells manipulated by cell and gene therapies.
License Property
The platform identifies multiple diseases and may be used to track treatment effectiveness, including immunotherapy. Disease intrusion and cell malformation, including cancer, are first detected in the body by the immune system, which is energized to rid the body of the malignancy. The initial immune response is intricate, deploying different metabolic pathways and subtypes of cells.  The platform technology is designed to detect and interpret these differential metabolic responses.

Patented ImmunoBiopsyâ„¢ immunometabolism platform with a goal of (I) developing and validating diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Licensee in manufacturing and processing of its cell and gene therapies; (ii) developing new assays to enhance the potency of cell and gene therapies for use within its point-of-care (POCare) platform; and (iii) developing companion diagnostics for potential enhanced patient targeting of cell and gene therapies.

Field of Use
ImmunoBiopsy platform non-invasively measures the metabolic state of the immune system and acts as a diagnostic link to early diseases.

ImmunoBiopsy platform has shown promise in early detection of cancer. The Parties look forward to leveraging this technology in a number of key areas within our POCare platform.

Licensee will use ImmunoBiopsy to help develop and validate diagnostic kits and create new assays to strengthen the potency of cell and gene therapies.  Licensee will also develop companion diagnostics to identify those patients most likely to respond to appropriate therapies.

IPSCIO Record ID: 270501

License Grant
With the Joint Venture Agreement (JVA), the parties will collaborate in the clinical development and commercialization of the products.

In addition, under the JVA, the Company shall, subject to fulfilment of the obligations to the JV, grant the JV an exclusive license to certain intellectual property of the Company as may be required for the JV to develop and commercialize the Products in the Territory, subject to minimum sales obligations.

License Property
The licensed property is the intellectual property needed for the development and commercialization of the products relating to cell and gene therapy products.

Licensor is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. Another platform is comprised of a specialization in cell manufacturing and development.

Field of Use
This agreement pertains to the medical industry relating to cell therapy.

IPSCIO Record ID: 269376

License Grant
With the Joint Venture Agreement (JVA), the Licensor and the Greek Licensee will collaborate in the clinical development and commercialization of the Company’s products   Under the JVA, the Company shall, subject to fulfilment of Licensee’s terms to the JV, grant the JV Company an exclusive license to certain intellectual property of the Company as may be required for the JV Company to develop and commercialize the Products in the Territory.
License Property
The licensed property is the intellectual property needed for the development and commercialization of the products relating to cell and gene therapy products.

Licensor is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. Another platform is comprised of a specialization in cell manufacturing and development.

Field of Use
This agreement pertains to the medical industry relating to cell therapy.

IPSCIO Record ID: 270502

License Grant
With the Joint Venture Agreement (JVA), the parties will collaborate in the clinical development and commercialization of the products.

In addition, under the JVA, Licensor shall, subject to fulfilment of the obligations grant the JV, an exclusive license to certain intellectual property of First Choice as may be required for the JV to develop and commercialize the Products globally.

Additionally, and for separate consideration, First Choice shall be granted a limited, non-exclusive license to certain rights relating to the Human Papilloma Virus.

License Property
The licensed property is the intellectual property needed for the development and commercialization of the products relating to cell and gene therapy products.

Licensor is a biotechnology company specializing in the development, manufacturing and provision of services in the cell and gene therapy industry. The Company is focused on the development of proprietary cell and gene therapies, including the autologous trans-differentiation technology, and therapeutic collaborations and licensing with other pre-clinical and clinical-stage biopharmaceutical companies and research and healthcare institutes. Another platform is comprised of a specialization in cell manufacturing and development.

Field of Use
This agreement pertains to the medical industry relating to cell therapy.

IPSCIO Record ID: 270500

License Grant
With the Joint Venture Agreement (JVA), the Greek parties will collaborate in the clinical development and commercialization the products worldwide. In addition, under the JVA, Licensor shall, subject to fulfilment of the Company’s terms to the JV, grant the JV Company an exclusive license to certain intellectual property of Licensor as may be required for the JV Company to develop and commercialize the Products globally.
License Property
The intellectual property are products needed for the development, manufacturing and provision of services in the cell and gene therapy industry.
Field of Use
This agreement pertains to the medical industry.

IPSCIO Record ID: 346226

License Grant
University granted us an exclusive, worldwide license under such patents and a nonexclusive royalty-bearing, worldwide license for such know-how to research, develop, commercialize and manufacture FCR001 and products containing FCR001 in all fields, without limitation. University also granted us the right to grant sublicenses in accordance with the University License Agreement.
License Property
The rights granted relate to certain licensed patent rights and know-how related to human facilitating cells for the Facilitated Allo-HSCT Therapy.

Aallogeneic hematopoietic stem cell transplantation (allo-HSCT), called Facilitated Allo-HSCT Therapy.  

The product candidate, FCR001, which is central to Facilitated Allo-HSCT Therapy, is a novel allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor, who is also the organ donor in the case of organ transplantation. FCR001 is rapidly processed in the GMP facility using proprietary manufacturing methods. Then, at the time of the transplant, FCR001 is administered to the recipient following nonmyeloablative conditioning, which is designed to be less toxic than myeloablative conditioning. A fully myeloablative conditioning regimen consists of a combination of agents and high doses of total body irradiation that destroy hematopoietic stem cells (HSCs) in the bone marrow and results in profound depletion of HSC-derived cells within one to three weeks following administration that is irreversible, and in most instances is fatal unless rescued by a stem cell transplant. The nonmyeloablative conditioning for FCR001 entails lower doses of chemotherapy and total body irradiation, causes less depletion of blood cells and does not require stem cell support for the recipient to resume the production of blood cells and platelets.

Allo-HSCT Therapy has the potential to treat a range of severe autoimmune diseases and severe non-malignant blood, immune and metabolic disorders, in each case with potential for similar outcomes to what has previously been observed with HSCT, while mitigating the toxicities, morbidities and extended hospital stay associated with the conditioning regimen typically required by HSCT.

Field of Use
Field of use is for to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders, in all fields, without limitation.

Facilitated Allo-HSCT Therapy could prevent organ rejection without the morbidity and mortality that has been associated with the use of lifelong anti-rejection medicines, also known as chronic immunosuppression.

IPSCIO Record ID: 330906

License Grant
University hereby grants to Licensee and Licensee hereby accepts an exclusive license, subject to any rights of the government in the Territory for the Field of Use, with the right to sublicense, under the Technology Rights and an exclusive license to the technology developed as of the Effective Date by Joshua M. Hare, M.D., that is not encumbered by any third party rights, which in University’s sole discretion, Is necessary to practice the Technology Rights to research, develop, make, have made, use, sell and import the Product(s) and to practice the Process(es) described and/or claimed In the Technology Rights,
License Property
Technology Rights shall mean Cell Aging Frailty-related MSC technology specifically set forth in Agreement.
Field of Use
Field of Use shall mean all fields for aging-related frailty.
Aging Frailty is a common geriatric condition that disproportionately increases a patient’s risk for poor clinical outcomes due to disease and injury, and is widely believed by geriatricians to ultimately be treatable.  MSCs are biological entities obtained from living humans that can pose risks to the recipient.  MSC therapies require many manufacturing steps. Cells must be harvested from donor tissue, isolated, and expanded in cell culture to produce a sufficient number of cells for use. Each step carries risks for contamination by other cells, microbes, or adventitious agents. The transfer of cells into a recipient can also carry risks and complications associated with the procedure itself, and a recipient may reject the transplanted cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.